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Background: In the past decade, the field of molecular biology has become increasingly quantitative; rapid
development of new technologies enables researchers to investigate and address fundamental issues quickly and in an
efficient manner which were once impossible. Among these technologies, DNA microarray provides methodology for
many applications such as gene discovery, diseases diagnosis, drug development and toxicological research and it has
been used increasingly since it first emerged. Multiple tools have been developed to interpret the high-throughput
data produced by microarrays. However, many times, less consideration has been given to the fact that an extensive
and effective interpretation requires close interplay between the bioinformaticians who analyze the data and
the biologists who generate it. To bridge this gap and to simplify the usability of such tools we developed
Eureka-DMA— an easy-to-operate graphical user interface that allows bioinformaticians and bench-biologists alike to
initiate analyses as well as to investigate the data produced by DNA microarrays.
Results: In this paper, we describe Eureka-DMA, a user-friendly software that comprises a set of methods for the
interpretation of gene expression arrays. Eureka-DMA includes methods for the identification of genes with differential
expression between conditions; it searches for enriched pathways and gene ontology terms and combines them with
other relevant features. It thus enables the full understanding of the data for following testing as well as generating
new hypotheses. Here we show two analyses, demonstrating examples of how Eureka-DMA can be used and its
capability to produce relevant and reliable results.
Conclusions: We have integrated several elementary expression analysis tools to provide a unified interface for their
implementation. Eureka-DMA's simple graphical user interface provides effective and efficient framework in which the
investigator has the full set of tools for the visualization and interpretation of the data with the option of exporting the
analysis results for later use in other platforms. Eureka-DMA is freely available for academic users and can be downloaded
at http://blue-meduza.org/Eureka-DMA.
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Since it was first introduced, the use of microarray
technology has been growing rapidly. The capacity to
survey the expression of thousands of genes in a single
experiment was proven to be extremely valuable for gene
expression profiling in many fields including basic
biological studies; medical diagnostics and personalized
medicine; drug discovery and development; toxicogenomics;
and cancer research [1-3]. Gene expression analysis hasCorrespondence: sagi.abelson@gmail.com
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reproduction in any medium, provided the ormoved well beyond the simple goal of identifying few genes
of interest. Other algorithms - for data visualization
and profiling, for assessing the involvement of genes
in particular molecular pathways and for searching
for the enrichment of a common ontology - have all
become important approaches, both for the pursuit of
hypothesis-driven inquiries and for the generation of new
hypotheses. Therefore, efficient analysis and interpretation
of the high volume data that is produced from microarrays
represents a major challenge; it may become the most
formidable obstacle, which biologists face once trying to
extract meaningful information from their experiments.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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array analysis are available. These range from free simple
programs that preform several basic tasks with relatively
limited scientific benefit to comprehensive programs,
which usually require prior knowledge in statistics; these
are also usually expensive and their complicated usability
usually restricts their usage to researchers already familiar
with the program's interface. Eureka-DMA is an application
that combines the simplicity of operation and data
management with the executions of multiple analysis
tasks to transform the high throughput data into
meaningful and understandable information. Eureka-DMA
provides algorithms for searching genes with differential
expression between groups, searching for enrichment
of pathways from KEGG PATHWAY database (www.
genome.jp/kegg/pathway.html) and enrichment of Gene
Ontology (GO) terms from the Gene Ontology database
(www.geneontology.org). Furthermore, it incorporates
options for the analysis of time series datasets and
expression profiling; all implemented, in an explicit,
easy-to-use graphical user interface (GUI), designed to
provide intuitive control throughout data processing.
The accessibility and simplicity of Eureka-DMA, combined
with the set of bioinformatics tools for full comprehensive
analysis should address a wide range of scientists:
specialists, as well as enthusiastic researchers with no
prior knowledge in bioinformatics.
Implementation
General software descriptions, aspects and design
Eureka-DMA software was written in MATLAB program-
ming language and can be run as a GUI in the MATLAB
environment or as a standalone Microsoft Windows
executable. Currently, multiple effective microarray
analysis algorithms are available as MATLAB functions
but their usability is restricted to researchers experienced
in computer science and familiar with MATLAB's
computing environment. In order to provide a unified
platform for an extensive interpretation of microarray
data, we integrated several MATLAB-analysis tools - either
as is or with slight modifications to allow proper usage
with Eureka-DMA's GUI - with new tools. Eureka-DMA's
main GUI enables simple and quick control throughout
the elucidation processes of the input data by the
interaction with several other sub-GUIs, all designed to
operate with limited user-input. Eureka-DMA's main GUI
also includes “ToolTip” explanation elements for the
different options, helping less advanced users understand
the purposes of the different software components. For
programmers and bioinformaticians who might wish to
edit the code, the script contains detailed explanations for
the embedded functions and is designed to enable
easy understanding along with easy accessibility for the
implementation of modifications. Last but not least,Eureka-DMA provides with functional annotation files for
mouse (M.musculus) and human, allowing the integration
of a standalone gene description tool, which enables the
withdrawal of the gene's summary paragraph from the
NCBI gene database (http://www.ncbi.nlm.nih.gov/gene)
into the main GUI and to generate description reports
about genes of interest. The appropriate species is
recognized automatically according to the user data
file and does not require user input.
Loading and exporting of data
It is necessary that raw data will be input as Windows
Excel or text files. These familiar file formats spare users
from dealing with multiple and less common microarray
files received by different manufacturers and can also
be easily obtained by exportation from the various
microarray manufacturer company's softwares. When
pulling data from microarray databases, such as Gene
Expression Omnibus (GEO) [4] and ArrayExpress [5],
small manual adjustments may be required. The download
package provides example data files that can be used either
as a template or to experiment with Eureka-DMA different
options. Results can be exported at any time during the
analysis into ‘xls’, Windows Excel or ‘txt’ file formats for
further process of the data with other external tools.
Furthermore, the different visualization tools enable
exportation into common figure formats.
Normalization of Raw data
Microarrays are intended to detect the expression level
variation between different samples, making normalization
an important preceding step to any analysis. A number of
normalization methods have been designed to address
the many reasons which can lead to non-biological
inconsistency between samples. Quantile normalization is
one method which is frequently used when interpreting
microarray data [6]. Subject to user decision, when a
set of arrays is available, this method will make the
distribution of the intensities for each array the same;
this process can be tracked with the visualization box
plot tool in Eureka-DMA main GUI.
Filtering Non-relevant data
Eureka-DMA offers two options for subtraction of
transcripts which are expressed below background
intensities. 1) User defined p-value threshold: Raw
data is comprised with manufacturer specific probe
IDs assigned to internal controls for the calculation
of detection p-values [7]. When detection p-values are
available, the user can set a threshold to filter transcripts
with high detection p-values. 2) User defined intensity
threshold: In case that detection p-values are not available,
the user can estimate and set an intensity threshold
to filter transcripts with low intensities, based on prior
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will have low intensities when liver tissue is tested) or
observation of the raw data for the internal negative
controls [8]. It is to be noted that for both options,
subtraction of transcripts is done only when all the
samples do not meet the criteria, thus avoiding the
elimination of those transcripts which did not get detected
in only part of the samples.
Detecting differential expression among conditions
Eureka-DMA provides several options for the detection
of genes that exhibit sufficient variation across measured
conditions. Volcano plot-display of significance versus
gene expression ratio (fold change) can be created in
cases where the data can be divided into two groups, i.e.
experimental group and control group [9]. Updating the
main GUI for those genes that are considered to be
significantly differentially expressed can be initiated
through the volcano plot sub-GUI by the user adjustment
of the fold change and/or p-value cutoffs. When the data
contain more than two conditions, e.g. time series data, a
differential expression can be defined by measuring the
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Where A = vector of 1 through the number of samples
and B = vector of the gene's intensities across samples.
Genes that pass the user defined r threshold will be
displayed by a rank order, determined by the intra-group
variation and the differential expression of the gene
between the groups. Additionally, Eureka-DMA provides
a filtering option based on minimal variation criteria
across samples [8].
Pathway enrichment analysis
Mapping genes on cellular pathways is one of the primary
goals in the analysis of transcriptomic data and is very
important for inferring biological mechanisms of diverse
biological conditions. Eureka-DMA contains a statistical
feature that seeks biological and chemical pathways
from KEGG pathway database that are significantly
over-represented in the user's gene list. With respect to a
background set of genes, hypergeometric probability
density test [10] is conducted to check whether the
number of differentially expressed genes from the user's
data was greater than expected by chance. Nominal
p-values are assigned and the user can browse through
the enriched pathways and create an illustration of
the pathway with the differentially expressed geneshighlighted. It is to be noted that this analysis can be
initiated with any list of genes and is not dependent
on any previous analyses.
Functional enrichment of gene ontology
After identifying the differentially expressed genes,
one will wish to ascribe them some biological meaning.
Identification of significant co-clustered genes with similar
properties (i.e. shares a cellular component, a biological
process, or a molecular function) can be achieved with the
‘Gene Ontology’ gene annotation scheme. Eureka-DMA
will apply the hypergeometric probability density test
[10] to pinpoint GO categories that are statistically
over-represented in the set of genes defined by the user's
previous analyses. Results may be illustrated as hierarchical
graphical displays, which provide the summarization of the
significance GO terms. Updating the GO database version
can be done automatically by user's choice.
Clustering, classification and visualization tools
Clustering and classification algorithms applied to high
dimensional expression data has the potential to provide
deeper insight to the underlying data structure and is
commonly used when a priori knowledge about specific
subgroups is lacking. Eureka-DMA supports several
widely used clustering and classification algorithms such
as hierarchical and K-means clustering [11-13], as well
as probabilistic principal component analysis (PPCA)
[14], all of which can be used in case the data suffer
from missing values [15]. Eureka-DMA also provides the
following visualization tools: an interactive volcano plot
that demonstrates genes with differential expression; a
heat-map accompanying the hierarchical clustering
analysis; a gene ontology bio-graph showing the terms
and their ancestry; an illustration of enriched KEGG
pathways; a bar plot; and, finally, box plots that display the
differences between all the analyzed entries across all
samples or the differences between single entries across
the user defined groups. The variety of the provided
visualization tools can be utilized separately for their
intended use or in combination for quality control and
analysis assessment.
Primer design for RT-qPCR validation
Reverse transcription quantitative PCR (RT-qPCR) is often
used to validate gene expression measurements from
DNA microarray experiments. Eureka-DMA offers a
primer design tool that can either import the list of genes
from the software's main GUI or used as a standalone
without the requirement of any previous analyses. The
primer design GUI contains various execution options: 1)
cDNA sequence data can be imported directly from
GenBank (www.ncbi.nlm.nih.gov/genbank) or be entered
manually. 2) The user can choose to apply adjustable filters
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content, and melting temperature. 3) The user can choose
to use additional parameters to filter primers that contain
nucleotide repeats and primers that might form secondary
structures such as hairpins, dimers and cross dimerization.
4) The length of the desire transcripts is controllable.
The impact of individual filters can be observed in a
2 dimensional plot that can also reveal the existence
of problematic regions within the cDNA transcript.
Results and discussion
Eureka-DMA has been tested on a number of data sets in
order to assess the program’s capability to deliver
meaningful and relevant biological insights regarding
the analyzed data. The results of two such analyses
demonstrating the feasibility of Eureka-DMA are reported
here. The first dataset contains expression data of 83
colorectal cancer (CRC) patients, divided into two
groups: responders and non-responders to FOLFOX
chemotherapy. The second dataset is obtained from a
time series study which assesses the global changes in
gene expression patterns, in the lungs of mice infected
with influenza virus, over a period of 60 days.
Analysis of colorectal tumors of responders and
Non-responders to FOLFOX chemotherapy
Publicly available raw expression data for 83 CRC generated
using the Affymetrix Human Genome U133 Plus 2.0
platform was downloaded from the GEO online database
[4] as two separate DataSet SOFT files. This study [16]
describes tumor samples - including 56 primary CRCsFigure 1 Data summarization by probabilistic principal component an
based on the contribution scores of the first two components. (A) Discrimina
responders and non-responders to FOLFOX therapy is shown as indicated inand 27 metastatic lesions - that were obtained from
different patients before therapy. The investigators
divided the samples into training and test sets. The
training set was used to identify classifier genes that are
able to predict responders to FOLFOX therapy; after
which the classifier signature was used on the test set in
order to evaluate its sensitivity and specificity. Random
Forests algorithm [17] was used for the identification of
the predictor genes. Since the classifier group of genes
was supported by limited biological meaning, we
independently applied Eureka-DMA and conducted
detailed biological analysis and interpretation. The
merged training and test sets data was loaded into
Eureka-DMA and subjected to normalization. Based
on the intensity values of the chip’s internal negative
controls, probes with intensity values below 90 across
all samples were filtered out. Expression profiles of
the 31826 remaining probes, compared across samples
by PPCA, revealed obvious separation between primary
tumors and metastatic lesions (Figure 1A), placing them
in separable regions in the reduced dimensional space.
However, when highlighting samples from response and
non-response patients (Figure 1B) we observed no dis-
tinguishable clusters. Additionally, there was no indication
of apparent relation in responsiveness to FOLFOX with
primary nor metastatic lesions (Figure 1A and B). By using
Eureka-DMA's volcano plot tool, we identified a list
of 77 probes that are differentially expressed between
responders and non-responders samples by at least 2 fold,
at significant levels of p-value < 0.05 (Additional file 1,
Figure 2). Interestingly, the 14 classifier genes publish inalysis. PPCA results are provided as two-dimensional representations
tion between metastatic lesions and primary tumors and (B) between
the color capture.
Figure 2 Volcano plot illustration of the double filtering criterion. 77 probes were significantly differentially expressed by at least 2 folds at
p-value < 0.05 between responder and non-responder patients. Through Eureka-DMA's interface, genes were described and assigned to one or
more of the different groups indicated.
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responders to FOLFOX therapy with high accuracy [16];
however, when checked individually one could see that
the expression of these genes only slightly differed
between the responders and non-responders groups
(fold change < 1.5, p-value < 0.05). Therefore, we areFigure 3 Differential expressions of secreted proteins and theirs trans
percentiles of 3 representative differentially expressed (A) transcripts obtained
In each plot, left boxes indicate expression in the non-responders group andproviding here a completely new elucidation of the data
and we are strengthening our interpretation with robust
published evidence. By investigating the differentially
expressed genes with Eureka-DMA's gene description tool
we notice that the list can be divided into 3 major groups,
all of which contain transcripts with a higher expressioncripts. Box plots illustrations of the median and the 25th and 75th
by Eureka-DMA's analysis and (B) proteins identified by Hyung et al. [20].
right boxes indicate expression in the responders group.
Figure 4 Changes in gene expression in the complement and coagulation cascades. Illustration of Eureka-DMA's top ranked KEGG pathway.
Yellow boxes indicate genes that were found to be differentially expressed between responder and non-responder patients.
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Figure 2). Group 1 consists of 5 probes corresponding
to 4 genes. CYP2C9, CYP2E1 and CYP2C8 belong to
cytochrome P450s superfamily of proteins, which
represents a large class of heme-containing enzymes that
catalyzes the metabolism of multitudes of exogenous
substrates and participates in their inactivation [18].
FMO3 belong to the flavin-containing monooxygenase
enzyme family involved in the oxidation of nucleophilic
atoms, which produce more polar substances as aprelude to excretion [19]. Group 2 consist of 40 probes
corresponding to 31 genes that encode different serum
proteins. In a recently published paper by Hyung et al.
[20], profiling of N-glycosylated proteins in the serum of
advanced breast cancer patients was performed in
order to discover serum biomarkers for chemoresistance.
Twenty three proteins were identified to be differentially
expressed between patients defined as sensitive and
patients defined as resistant to docetaxel and doxorubicin
treatment. The expression pattern of several proteins was
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our analysis we found transcripts encodes to 10 out of the
23 aforementioned proteins (Additional file 1). Even
though patients bearing different type of cancer and under
different treatment regimen were investigated, it is very
unlikely that these results are consequence of chance
(p = 9.29e-20 by hypergeometric probability density test);
This is further supported by other studies, which
demonstrate elevated expressions of different serum
proteins found in our analysis and in patients with
chemoresistant tumors [21,22]. Moreover, since different
profiling methods were used in the two studies - peptide
separation and quantification from patients serum using
LC/MS/MS compared with GeneChip microarray of
tumor samples - our results also imply that the high levels
of several serum proteins found at Hyung et al. study in
chemoresistant patient's blood (Figure 3), might be due to
the consequence of biological processes that occurred in
the tumors rather than patient-inherent causes. Group 3
consists of 12 probes, corresponding to 10 genes, all
related to lipid metabolism, transport and/or synthesis.
Even though two genes in this group - APOA1 and AMBP
were also identified to be elevated in paclitaxel resistance
ovarian cell lines [23], the relevance and contribution of
these genes to the resistance phenotype as a group is
yet to be determined. By using Eureka-DMA pathway
enrichment analysis tool we were able to further support
our unbiased categorization of the genes into the 3 groups.
By setting a threshold of p-value < 0.05 we found
enrichment of 17 pathways (Additional file 2) including
the complement and coagulation cascades (Figure 4) and
PPAR signaling pathway, which were described before toFigure 5 Hierarchical clustering and heat map of genes which were fo
are specified. At the top, genes that show reduced expression which start
expression which starts at around day 5. Log-transformed expression databe dysregulated in several tumor types [24] and have been
implicated with the formation of resistant prostate cancer
in mice [25]. Moreover we found enrichment of pathways
involved in xenobiotic and drug metabolism along with
multiple other metabolic pathways. This implies that drug
resistance in CRC may partially be acquired by processes
that regulate drug activity and availability. Taken together,
the analysis of the data using Eureka-DMA exposes
reasonable and relevant information regarding the
comparison made here. Literature mining of several differ-
ential genes and pathways, which were highlighted by our
analysis, revealed their aberrant regulation in other cancer
types under other treatment regimens, suggesting common
mechanisms that may regulate drug resistance. Given the
strong statistical enrichment of the complement and
coagulation pathways along with elevated expression
of several drug metabolism genes, suggest the importance
of a further examination of the exact underlying molecular
and metabolic processes as they may hold the key for
understanding FOLFOX resistance in CRC.
Analysis of the lung transcriptome in mice infected with
influenza A virus
In order to demonstrate Eureka-DMA's credibility, we
applied it to dataset published by Pommerenke et al. [26].
This study was conducted using Agilent's Whole Mouse
Genome Microarray 4x44K and recorded gene expression
changes in mouse lungs after a non-lethal infection
with influenza A virus over a period of 60 days.
Pommerenke et al. identified differentially expressed
genes by comparing each group of samples, classified by
the number of post infection days, to the non-infected,und to be differentially express across 14 day's period. 2 clusters
s at around day 2 and at the bottom, genes that show elevated
are mean centered and hierarchically clustered by gene.
Figure 6 Gene ontology structure mapping. Hierarchical illustration of predominant gene ontology terms with respect to (A) the cluster of
genes that demonstrate reduce expression over time and to (B) the cluster of genes that demonstrate elevated expression over time. Color
coding reflects the terms enrichment p-value.
Abelson BMC Bioinformatics 2014, 15:53 Page 8 of 10
http://www.biomedcentral.com/1471-2105/15/53mice-control groups. A cutoff of two-fold change in
expression levels was chosen. Density cluster analysis of
all the differentially expressed genes was then used to
find genes with similar expression profiles. In total,
eight clusters were discernible and been subjected to
an additional analysis in order to determine over-
representation of gene ontology terms. Among the
eight, two major clusters were observed. The first is a
cluster of genes with a reduced expression starting at
day 2 following infection; the expression of most of the
genes in that cluster returns to baseline levels following
day 14. The second cluster includes genes with an elevatedexpression starting at day 5, and again, following day 14
the expression of most of the genes in that cluster returns
to baseline values. The two clusters were associated with
developmental process, vasculature development and
blood circulation GO terms and with leukocyte activation,
mitosis and T cell activation GO terms respectively.
The purpose of this exercise is to demonstrate the
credibility of Eureka-DMA by extracting and validat-
ing results originated by different analysis tools and
methodology rather than performing in-depth bio-
logical analysis of mice immune response to influenza
A virus infection. Therefore, we choose to focus on
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biologic insights regarding genes which show reduced and
increased expression across 14 day's period. The relevant
quantile normalized data set was downloaded from the
ArrayExpress database [5], uploaded into Eureka-DMA
and the samples were categorized into their corresponding
time groups by using Eureka-DMA's tool for the detection
of differentially expressed genes in time series data sets. A
threshold of r < 0.6 was chosen following the filtering of
the 50 percent of the probes that demonstrate the lowest
variance across samples. This was done in order to also
expose genes which do not exhibit perfectly linear
expression pattern across time and since the dataset
contains uneven group sizes. The identified probes
were subjected to K-means clustering which split the data
into two clusters that revealed similar expression
patterns to the aforementioned clusters demonstrated
by Pommerenke et al. [26]. Hierarchical clustering
verified the reduced and elevated expression of the
genes in these clusters within the 14 days' time-frame
(Figure 5). Next, we assigned the clusters with putative
functional meaning and identified over-representation of
gene ontology terms. Similarly to Pommerenke et al.
observations, Eureka-DMA detected enrichment of the
developmental process and vasculature development GO
terms with several other GO terms related to ‘circulatory
system’ in the gene-cluster that demonstrates reduced
expression over time (Figure 6A). Furthermore, we detected
enrichment of the mitosis and T cell activation GO terms
with several other GO terms related to ‘leukocyte's
immune response’ in the gene-cluster that demonstrates
elevated expressions over time (Figure 6B). In this analysis
we used different algorithms compared to Pommerenke
et al. as well as a different methodology in order to extract
information regarding a specific time frame. The analysis
described here demonstrates Eureka-DMA's capability
to validate results obtained by different tools and its
credibility in the detection and interpretation of major
expression patterns in highly complex datasets
Conclusion
Eureka-DMA aspires to provide a unified and flexible
platform for microarray data analysis, interpretation and
visualization, and can be also used as a fast validation
tool for results obtained by different analysis methods.
It was programmed in MATLAB, exploiting many elements
from its various toolboxes while offering friendly integra-
tion with other essential features. Eureka-DMA is the only
implementation tool to provide the generation of reports
that include descriptive biological information regarding
genes of interests. It is also the only software for investiga-
tion and analysis of DNA microarray data to include a tool
for primer design. By its novel outline, this tool allows for a
quick access to the inseparable part of RTq-PCR validationthat ultimately leads to the complete analysis of the data.
The analysis in many other software-products is performed
“behind the scene” and provides only final output; this
disconnects the user from his data, potentially leading to
sub-optimal decisions. Eureka-DMA unique design on the
other hand, allows the user to conveniently navigate
through the data and understand easily how his actions
affect the outcome. Through minimal system requirements
and simplicity of interface, these tools can be conveniently
applied by a broader range of researchers, including
biologists with limited programming or scripting skills.
After testing and ensuring its capability of successfully
delivering biologically-meaningful and reliable results, it is
our hope that Eureka-DMA will be found useful to many
other in their various research areas. Eureka-DMA's
files and a step-by-step manual are freely available at
the software website and are also supplemented as
Additional files 3 and 4 respectively.Availability and requirements
Home page: http://blue-meduza.org/Eureka-DMA
Operating system: Windows, if used as a stand-alone.
Application or platform independent, if used under
MATLAB.
Requirements: If used under MATLAB: MATLAB 2010a
or newer, Bioinformatics, Statistics and Image Processing
Toolboxes are required. If used as a stand-alone applica-
tion, MATLAB Component Runtime (MCR) is required
(available to download with the software package).
Other requirements: Internet connection.
License: Free for non-commercial and academic use.Additional files
Additional file 1: Ordered list of differentially expressed genes with
theirs corresponding fold change and p-value.
Additional file 2: Ordered list of significant enriched KEGG
pathways.
Additional file 3: ZIP archive file that contains all the software files
needed in order to run Eureka-DMA in the MATLAB environment.
This archive contains the code.
Additional file 4: PDF file of Eureka-DMA Tutorial.Abbreviations
DMA: DNA microarray; GO: Gene ontology; GUI: Graphical user interface;
GEO: Gene expression omnibus; PPCA: Probabilistic principal component
analysis; RT-qPCR: reverse transcription quantitative PCR; CRC: Colorectal
cancer; MCR: MATLAB component runtime.Competing interests
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